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OBJECTIVES: The economic impact of therapeutic non-
compliance in chronic diseases has rarely been examined
following qualitative standards for economic evaluation.
This study illustrates the potential impact of non-
compliance on the cost-utility of chronic treatments using
the case of renal transplantation versus haemodialysis and
examines the economic scope for compliance enhancing
interventions. METHODS: Long term cost and outcomes
in compliant and noncompliant renal transplant pa-
tients were simulated in a Markov model. The cost 
and outcome data that were imputed in the model were
derived from a prospective study in renal transplantation
candidates. Probabilities of adverse events, graft rejection,
graft loss and death, in compliant and noncompliant renal
transplant patients were derived from literature. A soci-
etal viewpoint was taken. RESULTS: Compared with
dialysis, renal transplantation offers a better outcome 
in both compliant and non-compliant patients. Lifetime
costs after transplantation in the compliant patient group
are higher than lifetime dialysis costs and than life-time
costs in the non-compliant patient group, mainly because
compliant patients live longer after transplantation.
Long-term outcomes after transplantation are better for
compliant than for non-compliant patients. The mean
cost per quality-adjusted life-year gained (QALY) in 
compliant patients relative to non-compliant patients 
is €36,606.94/QALY (95% conﬁdence interval
[35,157.13–37,986.57]). CONCLUSIONS: This study
shows that renal transplantation is an optimal treatment
for end stage renal disease patients, regardless of patients’
level of compliance post-transplantation, as illustrated 
by the lower costs and better outcomes. In view of 
the incremental cost-utility ratio of haemodialysis, which 
is considered to be a cost-effective treatment, of
€65,912/QALY, it can be concluded that there is scope for
compliance- enhancing interventions. The improvement
of outcome in compliance justiﬁes the additional costs
that need to be borne and therefore the introduction of
compliance-enhancing interventions.
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OBJECTIVES: The Health Technology Assessment
(HTA) Committee of the Philippine Health Insurance
Corporation (PhilHealth) was established in 1999 to
develop reimbursement policies on medical claims based
on the cost-effectiveness of tests and treatments. ME-
THODS: The most commonly prescribed drugs that 
PhilHealth does not reimburse are subjected to this assess-
ment Because randomized controlled trials provide the
best evidence of efﬁcacy and effectiveness, only system-
atic reviews of RCTs and individuals RCTs are included.
The intervention in the study should have at least the drug
being evaluated in one arm and a standard treatment in
the other arm. Electronic search is done through the Inter-
net in the MEDLINE by two independent searchers. Elec-
tronic search is also done in the CD version of the
Cochrane Library Two independent reviewers review all
abstracts and articles for possible inclusion. The full texts
of the selected abstracts are retrieved at a library network.
Two reviewers using a standard assessment form inde-
pendently assess the validity and applicability of the
included systematic reviews and clinical trials. Qualitative
and if appropriate, quantitative methods are used to
analyze and/or combine the results of the different studies
in order to come up with a summary measure of effec-
tiveness. RESULTS: Safety and cost-effectiveness data 
are obtained from the results of clinical trials, post-
marketing surveillance studies, ADR reports from local
and international sources and local retail drug costs.
CONCLUSIONS: If the drug is less cost-effective or safe
than the standard drug, then it is not recommended for
inclusion in the PhilHealth positive list of reimbursable
drugs. If the drug is more cost-effective and poses no addi-
tional risk compared with the standard drug, then the
drug is recommended for inclusion in the positive list pro-
vided that it is used for the conditions for which it was
found effective.
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OBJECTIVES: To describe the development of drug
wholesale price indices in Finland during in 1980–2002.
METHODS: Price indices covering study time span (The
Helsinki Research Institute for Business Administration
[1980–1990], IMS [1991–1994] and Statistics Finland
[1995–2002]) were combined to reliable price indices that
reﬂect the development of drug prices in general and in
different reimbursement categories. Two different index
clusters (1980 = 100 and 1990 = 100) were produced.
The latter enables more precise classiﬁcation of different
reimbursement categories. After constructing the nominal
indices, real price indices were produced by adjusting
nominal indices with Consumer Price Index (CPI, Statis-
tics Finland) and its sub-index Consumer Price Index for
Health Care (CPI-H, Statistics Finland). RESULTS: In
2002 the index (1980 = 100) for all drugs was 168 (CPI
